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Abstract
Objectives:  To describe the introduction and evaluate efficacy of photodynamic diagnosis with Hexvix for
detecting tumours and abnormal mucosal lesions during transurethral resection of bladder tumour (TURBT).
Subjects  and  methods:  Prospective study of consecutive eligible patients who underwent TURBT with aid
of Hexvix-guided cystoscopy in a single District General Hospital (NHS Trust in England).
The participants selected were patients suspected to have bladder cancer or enlisted to undergo TURBT.
The main outcome measures were the number of tumours or abnormal mucosal lesions that were missed
by white light cystoscopy (WLC) but detected by Hexvix, blue light cystoscopy (BLC).
Results: A total of 63 patients (39 males and 24 females; mean age 74 years; age range, 35–88 years) met
study criteria. 15 were excluded: in 6 intra-vesical Hexvix was retained for <1 h, and in 4, TURBT was
delayed by >1 h; of the remaining 53 patients, 5 were excluded for technical reason, failure of fluorescence.
Seventy five lesions were detected in the remaining 48 patients. Of these, 51 (68%) were detected by WLC
and BLC both. BLC detected additional 24 (32%) lesions that were missed by WLC. Of these lesions, 15
(20%) were cancer and 9 (12%) were inflammation or dysplasia.
Conclusion:  BLC with Hexvix was easily introduced into a Bladder cancer management protocol and well
tolerated by most patients. BLC increased diagnostic accuracy of cystoscopy during TURBT, although some
of the lesions it detected were false positive.
© 2014 Pan African Urological Surgeons’ Association. Production and hosting by Elsevier B.V. 
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Technique
Briefly, 85 mg of Hexvix was dissolved in 50 ml solvent and instilled
into the bladder via  a urethral catheter 1 h before TURBT. Patients24 
ntroduction
ver 10,000 people are diagnosed annually with bladder cancer
BC) in the United Kingdom, where it is the 7th most common can-
er [1]. Non-muscle-invasive BC (NMIBC) accounts for 75–85%
f all newly diagnosed BC cases [2]. The 5-year survival rate of
atients with bladder cancer confined to the mucosa (TaT1 NMIBC),
s 80–90% [3]. About 25–75% will develop recurrent disease [3,4].
any progress to muscle invasive BC (MIBC) or metastatic dis-
ase [5]. Of the TaT1 NMIBC recurrences, 25–60% may be due to
ncompleteness of TURBT because white light cystoscopy (WLC)
oes not visualize all tumour-bearing sites [6,7]. Indeed, check cys-
oscopies detect residual or recurrent disease in about 55% of cases
6–9].
he limitations of WLC led to the development of Photodynamic
iagnosis, PDD with 5-Aminolevulinate (5-ALA) and Hexam-
nolevulinic acid (HAL; trade name Hexvix) respectively. It has
een reported to improve recurrence-free survival (RFS) of patients
ith bladder cancer [7–18]. International expert panels have also
roduced guidelines for PDD with Hexvix, namely diagnosis of
MIBC that has not yet been subjected to TURBT, follow-up of
atients with NMIBC, additional testing of patients with positive
rine cytology but negative WLC, follow-up of patients with
ultifocal disease and suspected carcinoma in  situ  (CIS) [19,20].
 recent study by the Health Technology Assessment programme
f the National Health Service of the United Kingdom came to
hree conclusions. First, PDD detects BC more sensitively but less
pecifically than WLC and is better at detecting more aggressive
nd higher risk tumours, including CIS. Second, compared to WLC,
hen PDD is used in the initial TURBT, fewer residual tumours
re found by check cystoscopy and the RFS is longer. Third, it
s not clear whether PDD at TURBT reduces tumour recurrence
nd progression in the long term better than WLC. Nevertheless,
DD provides additional benefits at a cost that society may be
illing to pay [21]. The present study aimed to provide preliminary
vidence to justify the routine use of Hexvix in our hospital and its
ntroduction in all the Trust’s hospitals.
ubjects and  methods
DD with  Hexvix
exvix and 5-ALA are fluorochromes and haem precursors that
re administered through a urethral catheter into the bladder to
id tumour detection on the basis of fluorescence [16,22,23]. They
ccumulate in tumour cells that metabolize them stepwise into first
orphyrin and then protoporphyrin IX which generates a purplish
uorescence. This is detected as blue by D-light (Xenon lamp) by
 specially developed light cable and special filter mounted on the
ystoscope eye-piece which has dual blue and white light functions.
his allows cystoscopic visualization of the tumours under white
nd blue light respectively (Fig. 1).
he chemical structure of Hexvix and 5-ALA are very similar:
exvix is essentially 5-ALA plus a lipophilic hexyl moiety. How-
ver, Hexvix has four times the fluorescent power of 5-ALA. Hence,
lthough 5-ALA was developed first and is available for oral and
ntravesical use, it is often replaced by Hexvix, which is currently
nly available for intravesical instillation. Hexvix is supplied as a
owder that is dissolved in a 50 ml buffer solution before instil-
ation into the bladder. The patient is expected to retain it withinS.O. Osaghae, D.T.L. Turner
he bladder for at least 1 h prior to TURBT (by contrast, 5-ALA
ust be retained for 2–3 h before TURBT). Hexvix accumulates in
ancerous bladder tissue and after illumination with blue light cys-
oscopy (BLC), a clearly visible purplish fluorescence is observed
Fig. 1a).
exvix was developed by Photo cure, ASA, Oslo, Norway and has
een available, to UK Urologists, since about 2003.
rospective trial
his prospective study of 63 consecutive patients with history of BC
as performed between January 2009 and November 2010. The
atients were included either because they had new presentation
ith bladder tumour, recurrent BC, positive urine cytology but a
egative WLC or suspected CIS. Study approval was obtained from
he Hospital Clinical Governance Committee. All patients consented
o PDD with Hexvix.Figure  1  Blue light chemistry and tumour detection.
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Tumour detected by special 
PDD cystoscope eye-piece
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visualisation of tumour
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HAL and 5-ALA
Bladder tumour
Administered into 
bladder 1 hr before 
operation
Cancer cells 
metabolise 
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Blue light chemistry and tumour detection Results
Sixty three patients (39 males and 24 females) age range 35–88
(mean 74) were recruited and consented to undergo Hexvix-guided
cystoscopy (Fig. 2). Of these, 35 (55.6%) were new tumours, 20
(31.7%) recurrent tumour, 5 (7.5%) positive urine cytology without
evidence of bladder tumour in conventional WLC and 3 (4.8%)
suspected CiS (Table 1). Excluded were 6 patients who failed to
retain Hexvix for 1 h, 4 (6.4%) where there was delay in cystoscopy
beyond 1 h and 5 (7.9%) due to technical failure. The cystoscopy
Study flow chart
Inclusion
n = 63
Male = 39
Females = 24
Age range = 35 – 88
Mean age = 74
Exclusion x 10
Nexvix retained
<1 hr x 6
TURBIT delayed
>1 hr x 4
Exclusion x 5
Failure of
fluorescence x 5
Consent
Hexvix into Bladder
Study Criteria
met by 53pts
48pts for
analysis
WLC + BLC BLC alone
n = 15
(68%)
Cancer
KEY
75 lesions
detected in total
n = 24 (32%) 
inflammination
Dysplasia
n = 51
(68%)
n = 24
(32%)Figure  1  (Continued. )
who retained the intravesical Hexvix underwent cystoscopy with a
Karl Storz PDD camera head with dual blue and white light func-
tionality 60 min later. Those patients who were unable to retain
intra-vesical Hexvix for 1 h and those who though retained Hexvix
for 1 h, there was failure of fluorescence during cystoscopy were
excluded from the study.
Endoscopically, the bladder mucosa was inspected in a stepwise
fashion under WLC and BLC. A map of all tumours and abnormal
areas seen were recorded separately and either resected or biopsied.
The following steps were followed: First, during preliminary cys-
toscopy, presence of control fluorescence was noted in bladder neck.
Second, fluorescence in the main tumour and elsewhere in the blad-
der was recorded. Third, all fluorescent areas outside the main
tumour were biopsied using cold cup or loop as appropriate. Fourth,
the main tumour was resected separately under WLC. Finally, to
confirm complete resection of the main tumour and biopsy of all
the abnormal-looking mucosa, BLC was performed. The locations
from which the biopsies were obtained and the histology results
including those recorded by BLC alone were recorded in the study
protocol (Appendix).
WLC: Wight light cystoscoscopy
BLC: Blue light cystoscoscopy
Figure  2  Study flow chart.
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Table  1  Indications for blue light cystoscopy (n  = 63) and reasons for exclusion (n  = 15).
Indication for BLC Number Cases excluded failure to retain Hexvix Delay in cystoscopy Technical failure
New tumour 35 (55.6%) 5 1 1
Recurrent tumour 20 (31.7%) 1 3 4
Positive cytology but negative WLC 5 (7.9%) – – –
Suspected CiS 3 (4.8%) – – –
Total 63 6 (9.5%) 4 (6.4%) 5 (7.9%)
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Tn the remainder 48 patients that fulfilled the criteria, resulted in
etection of a total of 75 lesions of which 51 (68%) were visualized
ith both WLC and BLC. 24 (32%) lesions comprising 15 (20%)
ue to cancers and 9 (12%) inflammation were only obvious on BLC
Table 2). Thus, the addition of BLC led to the detection of extra
esions that were missed by WLC. These included high grade CiS
nd G3pT1 and false positive cases due to inflammation.
iscussionn this study, the papillary tumours or lesions with a raised mucosa
ere usually detected by both WLC and BLC. However, 15 cases
20%) of all lesions detected in this study were flattish CiS and G1-
pTa-1 tumours which were only detected by using BLC. This is
o
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Table  2  Histology of detected lesions.
Lesions detected by 
both white light and PDD 
(n = 51 out of 75 lesions)
GG2pTaG1/2p TaG1pTaG1pT1CISG3pT1Inflammation/
dysplasia
9
2
5
3
1
1
1
2
6 6 6
9
5 ignificant because the lesions may have been detected at a sub-
equent cystoscopy and probably misdiagnosed as a recurrence.
revious studies have also shown that 25–60% of BCs are not diag-
osed at the time of TURBT [6–9]. Notably, 9 of the 24 lesions
hat were detected by BLC alone (12% of all 75 lesions) were due
o inflammation. This relatively high frequency of inflammation
etection with BLC alone (false positive) was probably a reflection
f our learning curve.
he limitations of this study include the possibility of bias of the
perating surgeon in favour of BLC. This can be eliminated by per-
orming a randomized study where half of the patients are examined
fter WLC-guided resection by BLC and the other half are examined
fter BLC-guided resection by WLC.
Additional lesions detected 
by only PDD, 32% 
(n = 24 out of 75 lesions)
G2pT1G2pT2G3pT22pTx
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Expert panels in the United Kingdom and Europe have recom-
mended that BLC should be used routinely in all cases of initial
TURBT, follow-up rigid cystoscopy (if Hexvix not used previ-
ously), positive urine cytology but negative WLC and follow-up
of patients with multi-focal disease and CIS [19,21]. Our experi-
ence, feedback after presentations and discussions in our Trust wide
multidisciplinary team meeting (Audit of Hexvix: Lessons learned
and implications for clinical practise, October 2010. Unpublished)
and during the British Association of Urological Surgeons North
London Regional meeting (Audit of Hexvix: A district general hos-
pital experience, December 2010. Unpublished), indicate that these
expert recommendations are broadly accepted apart from the use of
BLC in all new cases.
Thus whether BLC should be used in all initial TURBTs or only in
selected cases remains controversial. There are two main objections
to the use of BLC in all new cases. First, the risks of prolonged expo-
sure to Hexvix or its use during pregnancy is not known [23]. Second,
since large tumours are usually well visualized by WLC, and the
aim of resection is often pathological staging, it is unclear whether
TURBT of large tumours requires BLC at the initial resection. This
is because many of these patients will ultimately require second look
cystoscopy, at which point BLC can be performed. This selective
approach, is not only associated with lower costs, it also allows asso-
ciated superficial lesions to be identified, biopsied and/or resected
during the mandatory precautionary second look. In any case, we
have found that when a large papillary tumour is associated with
multiple tiny satellite lesions, to ensure complete resection, it is
useful to perform PDD at the initial TURBT to ensure complete
resection.
We found that Hexvix is easily introduced into a BC management
protocol after Hospital Clinical Governance Committee approval
is obtained and the appropriate equipment (which should be com-
patible with existing endoscopic equipment) is purchased. As a
result of our experience, the use of Hexvix has been introduced to
the other Trust hospitals. Our study and others [7–18] show that
Hexvix improves BC detection, and the other studies show that
Hexvix improved RFS, and that society appears to be willing to
pay for BLC [21]. However, it remains to be seen whether Hexvix
will be universally adopted by Urologists and if so, whether it ulti-
mately translates into reduced disease progression and improved
long-term cancer survival (oncological outcome) that justifies the
cost of intervention.Conclusions
PDD with Hexvix is a valuable adjunct in the endoscopic manage-
ment of BC. It is easy to introduce into a BC management protocol
U
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ith a short learning curve for experienced Urologists. It is well
olerated by most patients and has been proved to increase the
etection of tumours during TURBT, albeit with some false positive
esults.
he recommendation of Expert panels that PDD should be per-
ormed in all cases of initial TURBT is controversial. An alternative
pproach may be to recommend the routine use of Hexvix during
he initial TURBT selectively based on the endoscopic characteris-
ics of the tumour and patient history. However, it has a useful role
n management of patients with positive urine cytology but negative
LC, multifocal disease and CIS.
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ppendix.
STUDY  PR OTOCOL
PILGRIM HOSPITAL HEXVIX AUDIT
Pa ent details or label Date of procedure..........
Day case: ..........
24 hour stay: ..........
In-pa ent: ..........
Minutes HexVix in bladder : ........
Indica on Please  ck those that apply
New tumour
Recurrent tumour
Posi ve cytology
Target biopsy of CIS
Cystoscopic Findings Please  ck
Control fl uores cence  seen  Y N
Tumour s een + white light + fluores cen ce 
Tumour s een + white light - fluores cence
Mucosal a bnormal ity + white light + fluores cen ce
Mucosal a bnormal ity - white light + fluores cen ce
Mucosal a bnormal ity + white light - fluores cence
Mucosal  normal
Diagram:
Histology Plea se  ck
Tumour
Muscle  included
Mucosal a bnormal ity
Diﬃcul es/complica ons:
Follow-up result Date Follow-up result Date
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